IBDEI1FX ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25544,1,4,0)
 ;;=4^V01.79
 ;;^UTILITY(U,$J,358.3,25544,1,5,0)
 ;;=5^VIRAL DIS CONTACT NEC
 ;;^UTILITY(U,$J,358.3,25544,2)
 ;;=^331577
 ;;^UTILITY(U,$J,358.3,25545,0)
 ;;=V01.81^^147^1605^2
 ;;^UTILITY(U,$J,358.3,25545,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25545,1,4,0)
 ;;=4^V01.81
 ;;^UTILITY(U,$J,358.3,25545,1,5,0)
 ;;=5^CONTACT/EXPOSURE TO ANTHRAX
 ;;^UTILITY(U,$J,358.3,25545,2)
 ;;=^328701
 ;;^UTILITY(U,$J,358.3,25546,0)
 ;;=V01.82^^147^1605^3
 ;;^UTILITY(U,$J,358.3,25546,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25546,1,4,0)
 ;;=4^V01.82
 ;;^UTILITY(U,$J,358.3,25546,1,5,0)
 ;;=5^EXPOSURE TO SARS
 ;;^UTILITY(U,$J,358.3,25546,2)
 ;;=^329963
 ;;^UTILITY(U,$J,358.3,25547,0)
 ;;=V01.89^^147^1605^1
 ;;^UTILITY(U,$J,358.3,25547,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25547,1,4,0)
 ;;=4^V01.89
 ;;^UTILITY(U,$J,358.3,25547,1,5,0)
 ;;=5^CONT/EXP TO OTHER COMM DISEASE
 ;;^UTILITY(U,$J,358.3,25547,2)
 ;;=^328661
 ;;^UTILITY(U,$J,358.3,25548,0)
 ;;=V02.60^^147^1606^6
 ;;^UTILITY(U,$J,358.3,25548,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25548,1,4,0)
 ;;=4^V02.60
 ;;^UTILITY(U,$J,358.3,25548,1,5,0)
 ;;=5^VIRAL HEPATITIS CARRIER, UNSPE
 ;;^UTILITY(U,$J,358.3,25548,2)
 ;;=^295173
 ;;^UTILITY(U,$J,358.3,25549,0)
 ;;=V02.61^^147^1606^3
 ;;^UTILITY(U,$J,358.3,25549,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25549,1,4,0)
 ;;=4^V02.61
 ;;^UTILITY(U,$J,358.3,25549,1,5,0)
 ;;=5^HEPATITIS B CARRIER
 ;;^UTILITY(U,$J,358.3,25549,2)
 ;;=^317946
 ;;^UTILITY(U,$J,358.3,25550,0)
 ;;=V02.62^^147^1606^4
 ;;^UTILITY(U,$J,358.3,25550,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25550,1,4,0)
 ;;=4^V02.62
 ;;^UTILITY(U,$J,358.3,25550,1,5,0)
 ;;=5^HEPATITIS C CARRIER
 ;;^UTILITY(U,$J,358.3,25550,2)
 ;;=^317947
 ;;^UTILITY(U,$J,358.3,25551,0)
 ;;=V02.69^^147^1606^5
 ;;^UTILITY(U,$J,358.3,25551,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25551,1,4,0)
 ;;=4^V02.69
 ;;^UTILITY(U,$J,358.3,25551,1,5,0)
 ;;=5^OTHER VIRAL HEPATITIS CARRIER
 ;;^UTILITY(U,$J,358.3,25551,2)
 ;;=^317948
 ;;^UTILITY(U,$J,358.3,25552,0)
 ;;=V02.7^^147^1606^2
 ;;^UTILITY(U,$J,358.3,25552,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25552,1,4,0)
 ;;=4^V02.7
 ;;^UTILITY(U,$J,358.3,25552,1,5,0)
 ;;=5^GONORRHEA CARRIER
 ;;^UTILITY(U,$J,358.3,25552,2)
 ;;=^295174
 ;;^UTILITY(U,$J,358.3,25553,0)
 ;;=V02.9^^147^1606^1
 ;;^UTILITY(U,$J,358.3,25553,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25553,1,4,0)
 ;;=4^V02.9
 ;;^UTILITY(U,$J,358.3,25553,1,5,0)
 ;;=5^CARRIER-INFECTIOUS ORGANISM NEC
 ;;^UTILITY(U,$J,358.3,25553,2)
 ;;=^295176
 ;;^UTILITY(U,$J,358.3,25554,0)
 ;;=V08.^^147^1607^1
 ;;^UTILITY(U,$J,358.3,25554,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25554,1,4,0)
 ;;=4^V08.
 ;;^UTILITY(U,$J,358.3,25554,1,5,0)
 ;;=5^ASYMPT HIV STATUS
 ;;^UTILITY(U,$J,358.3,25554,2)
 ;;=^303392
 ;;^UTILITY(U,$J,358.3,25555,0)
 ;;=V49.0^^147^1608^9
 ;;^UTILITY(U,$J,358.3,25555,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25555,1,4,0)
 ;;=4^V49.0
 ;;^UTILITY(U,$J,358.3,25555,1,5,0)
 ;;=5^DEFICIENCIES OF LIMBS
 ;;^UTILITY(U,$J,358.3,25555,2)
 ;;=^295484
 ;;^UTILITY(U,$J,358.3,25556,0)
 ;;=V49.1^^147^1608^16
 ;;^UTILITY(U,$J,358.3,25556,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25556,1,4,0)
 ;;=4^V49.1
 ;;^UTILITY(U,$J,358.3,25556,1,5,0)
 ;;=5^MECHANICAL PROB W LIMBS
 ;;^UTILITY(U,$J,358.3,25556,2)
 ;;=^295485
 ;;^UTILITY(U,$J,358.3,25557,0)
 ;;=V49.2^^147^1608^17
 ;;^UTILITY(U,$J,358.3,25557,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25557,1,4,0)
 ;;=4^V49.2
 ;;^UTILITY(U,$J,358.3,25557,1,5,0)
 ;;=5^MOTOR PROBLEMS W LIMBS
 ;;^UTILITY(U,$J,358.3,25557,2)
 ;;=^295486
 ;;
 ;;$END ROU IBDEI1FX
